Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | AGXT | P21549 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14006337 | 1.00 | NPC1 (0.46) | NPC1RAB9ATSHRMEN1KMT2A | |
| SCHEMBL211957 | 1.00 | NPC1 (0.46) | NPC1RAB9ATSHRMEN1KMT2A | |
| Maleic Acid SCHEMBL6688994 | 0.88 | HCAR2 (0.56) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| Fumaric Acid SCHEMBL6689002 | 0.88 | HCAR2 (0.56) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| Maleic Acid SCHEMBL6688997 | 0.88 | HCAR2 (0.56) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| Succinic Acid SCHEMBL6684048 | 0.88 | ALDH1A1 (0.44) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2045290 | 0.82 | TSHR (0.50) | NPC1RAB9ATSHRMEN1KMT2A | |
| SCHEMBL11522499 | 0.82 | TSHR (0.50) | NPC1RAB9ATSHRMEN1KMT2A | |
| SCHEMBL15865984 | 0.81 | AGXT (0.48) | NPC1RAB9ASMN1; SMN2GAAIDO1 | |
| SCHEMBL2047060 | 0.80 | TSHR (0.48) | NPC1RAB9ATSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158046-A1 | BIOCOMPATIBLE BIODEGRADABLE FUMAGILLIN ANALOG CONJUGATES | Mersana Therapeutics, Inc (US) | 2013-06-20 | — | — | US | claimed |
| US-8399512-B2 | Biocompatible biodegradable fumagillin analog conjugates | MERSANA THERAPEUTICS, INC. (US) | 2013-03-19 | — | — | US | claimed |
| US-20120077941-A1 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2012-03-29 | — | — | US | claimed |
| US-8088868-B2 | oximation of cojugated homopolymers formed by addtion polymerization of conjugated diene monomer in the presence lanthanide copmpounds as polymerization catalysts; polymers used in the manufacture of tires having reduced hysteresis | BRIDGESTONE CORPORATION (JP) | 2012-01-03 | — | — | US | claimed |
| CN-101990441-A | Biocompatible biodegradable fumagillin analog conjugates | MERSANA THERAPEUTICS INC | 2011-03-23 | — | — | CN | claimed |
| EP-2217283-A2 | BIOCOMPATIBLE BIODEGRADABLE FUMAGILLIN ANALOG CONJUGATES | Mersana Therapeutics, Inc. (US) | 2010-08-18 | — | — | EP | claimed |
| US-7700655-B2 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-04-20 | — | — | US | claimed |
| WO-2009073445-A2 | BIOCOMPATIBLE BIODEGRADABLE FUMAGILLIN ANALOG CONJUGATES | MERSANA THERAPEUTICS, INC. (US) | 2009-06-11 | — | — | WO | claimed |
| US-20090148396-A1 | BIOCOMPATIBLE BIODEGRADABLE FUMAGILLIN ANALOG CONJUGATES | MERSANA THERAPEUTICS, INC. (US) | 2009-06-11 | — | — | US | claimed |
| US-20090105292-A9 | Glucocorticoid Receptor Modulator Compounds and Methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2009-04-23 | — | — | US | claimed |
| US-20070281959-A1 | Glucocorticoid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2007-12-06 | — | — | US | claimed |
| US-20070185110-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | claimed |
| US-20070185059-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | claimed |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-02-22 | — | — | US | claimed |
| EP-1718653-A1 | GLUCOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS- UTILITY | Ligand Pharmaceuticals Inc. (US) | 2006-11-08 | — | — | EP | claimed |
| EP-1649852-A1 | CHROMATOSIS REMEDIES | Institute of Medicinal Molecular Design, Inc. (JP) | 2006-04-26 | — | — | EP | claimed |
| WO-2005082909-A1 | GLUCOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS- UTILITY | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2005-09-09 | — | — | WO | claimed |
| US-4913722-A | HERBICIDES | ICI AMERICAS INC. (US) | 1990-04-03 | — | — | US | claimed |
| US-4877880-A | REACTING AN N-3-SUBSTITUTED ALLYL ANILINE WITH AN ARYLISOTHIOCYANATE, REACTING THE RESULTANT THIOUREA WITH A (TRIFLUORO-)METHANESULFONIC ACID | ICI AMERICAS INC. (US) | 1989-10-31 | — | — | US | claimed |
| EP-0318253-A1 | Iminophenylthiazolidines, process of preparation, and method of use | ICI AMERICAS INC. (US) | 1989-05-31 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185110-A1 | Antiallergic agents | NAT1, EPX, AHR | NPC1 4521/4885RAB9A 2704/4885TSHR 2963/4885 |
| US-20090105292-A9 | Glucocorticoid Receptor Modulator Compounds and Methods | NR3C1, NR3C2, MC2R | NPC1 1327/4885RAB9A 3084/4885TSHR 244/4885 |
| US-20070185059-A1 | Antiallergic agents | NAT1, EPX, AHR | NPC1 4551/4885RAB9A 2770/4885TSHR 3004/4885 |
| US-20070281959-A1 | Glucocorticoid receptor modulator compounds and methods | NR3C1, NR3C2, MC2R | NPC1 1327/4885RAB9A 3084/4885TSHR 244/4885 |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | TYR, XDH, XPA | NPC1 2599/4885RAB9A 3815/4885TSHR 3558/4885 |
| US-20090148396-A1 | BIOCOMPATIBLE BIODEGRADABLE FUMAGILLIN ANALOG CONJUGATES | VEGFA, FLT1, FLT4 | NPC1 2698/4885RAB9A 2268/4885TSHR 4350/4885 |
| US-20130158046-A1 | BIOCOMPATIBLE BIODEGRADABLE FUMAGILLIN ANALOG CONJUGATES | VEGFA, FLT1, FLT4 | NPC1 2698/4885RAB9A 2268/4885TSHR 4350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.